New controversy with Donanemab (marketed in the US as Kisunla)

dancsfo

Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer’s drug

https://www.bmj.com/content/386/bmj.q2010

kalainoffs

I'm looking for new users if Kisunla Thanks

Larrybee

Thanks for the info. Drug makers often manipulate clinical trial data in their favor and the FDA lets them get away with it.

Maru

I feel justified that we refused our neurologist's strong push to start the infusions. Even with the numbers that were given, we felt the risk was too great considering that DH already at vascular bleeds going on.